Brief: Pepgen Inc Expects To Report Initial Data From FREEDOM-DM1 Phase 1 Clinical Trial In 2024
20/02/2024 13:27
Feb 20 (Reuters) - PepGen Inc PEPG.O :
* PEPGEN RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR
PGN-EDODM1
FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1
* PEPGEN INC: EXPECTS TO REPORT INITIAL DATA FROM
FREEDOM-DM1
PHASE 1 CLINICAL TRIAL IN 2024
Source text for Eikon: ID:nGNX70DfFH
Further company coverage: PEPG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview